AI powered value Target hospitals looking to reduce perioperative risk with AI-assisted neuromuscular monitoring. Nerbio’s iTOF platform offers real-time, wireless TOF assessments via smartphones, enabling safer dosing of neuromuscular blockers and faster recovery times as a differentiator against bulky legacy systems.

Mobile first platform Leverage the mobile, app-controlled nature of iTOF to pursue opportunities in centers seeking cost-effective, scalable monitoring solutions without substantial capital expenditure. Emphasize faster deployment, ease of use, and remote data access for clinicians.

FDA cleared edge Highlight FDA clearance as a risk reducer and credibility booster when engaging procurement and clinical leadership. Position Nerbio against traditional monitoring vendors by stressing lower total cost of ownership and minimal on-site setup.

Growth and funding signals Note the company’s revenue range and recent funding as indicators of growth potential and product development momentum. Approach investors or hospital finance teams with a narrative around scalable AI-driven monitoring and expandability across hospital networks.

Platform expansion Explore cross-sell opportunities within hospitals by offering a roadmap to expand from iTOF to a broader AI-powered mobile monitoring suite. Emphasize compatibility with existing IT infrastructure and cloud-based data integration to support population health and perioperative workflows.